<DOC>
	<DOCNO>NCT01421186</DOCNO>
	<brief_summary>This open-label , multicentre , dose escalation study characterize safety preliminary efficacy human anti-CD38 antibody MOR03087 ( MOR202 ) , adult subject relapsed/refractory multiple myeloma , monotherapy adult subject relapsed/refractory multiple myeloma combination standard therapy .</brief_summary>
	<brief_title>A Phase I/IIa Study Human Anti-CD38 Antibody MOR03087 ( MOR202 ) Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Male female subject 18 year old 2 . Relapsed refractory multiple myeloma define : Parts A , B C : ( ) Failure least 2 previous therapy must include immunomodulatory agent proteasome inhibitor ( either together part different therapy ) ( ii ) All subject must document progression last prior therapy multiple myeloma Part D : ( ) At least 2 previous therapy include lenalidomide proteasome inhibitor ( ii ) All subject must document progression within 60 day last prior therapy multiple myeloma Part E : ( ) Received least one previous therapy ( ii ) All subject must document progression last prior therapy multiple myeloma 3 . Presence serum Mprotein ≥ 0.5 g per 100 mL ( ≥ 5 g/L ) / urine Mprotein ≥ 200 mg per 24hour period 4 . Absolute neutrophil count ( ANC ) ≥ 1,000 / mm3 5 . Haemoglobin ≥ 8 g/dL 6 . Ability comply study related procedure , medication use evaluation 1 . Primary refractory multiple myeloma 2 . History significant cerebrovascular disease sensory motor neuropathy toxicity grade 3 high 3 . Treatment systemic investigational agent within 28 day prior first study treatment 4 . Solitary plasmacytoma plasma cell leukaemia 5 . Previous allogenic SCT 6 . Prior therapy monoclonal antibody target CD38 antigen prior therapy IgG monoclonal antibody within 3 month prior first study treatment , IgM monoclonal antibody within 1 month prior first study treatment 7 . Active systemic infection 8 . Systemic disease prevent study treatment 9 . Multiple myeloma CNS involvement 10 . Previous treatment cytotoxic chemotherapy large field radiotherapy myeloma specific therapy within 28 day prior first study treatment ( radiation single site concurrent therapy allow ) 11 . Significant uncontrolled cardiovascular disease cardiac insufficiency ( New York Heart Association [ NYHA ] class III , IV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>MOR03087 ( MOR202 )</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>CD38</keyword>
</DOC>